Gross Profit Analysis: Comparing Eli Lilly and Company and Corcept Therapeutics Incorporated

Eli Lilly vs. Corcept: A Decade of Profit Growth

__timestampCorcept Therapeutics IncorporatedEli Lilly and Company
Wednesday, January 1, 20142566900014683100000
Thursday, January 1, 20154892500014921500000
Friday, January 1, 20167926300015567200000
Sunday, January 1, 201715564700016801100000
Monday, January 1, 201824603200016811600000
Tuesday, January 1, 201930098200017598300000
Wednesday, January 1, 202034829200019056500000
Friday, January 1, 202136069700021005600000
Saturday, January 1, 202239647300021911600000
Sunday, January 1, 202347589400027041900000
Monday, January 1, 202436624400001
Loading chart...

Igniting the spark of knowledge

Gross Profit Growth: Eli Lilly vs. Corcept Therapeutics

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit growth of Eli Lilly and Company and Corcept Therapeutics Incorporated from 2014 to 2023. Eli Lilly, a century-old giant, consistently outperformed with a staggering 84% increase in gross profit over the decade, peaking at $27 billion in 2023. Meanwhile, Corcept Therapeutics, a relatively newer player, showcased impressive growth, with a 1,750% increase, reaching nearly $476 million in 2023. This stark contrast highlights the dynamic nature of the industry, where established firms maintain dominance, yet emerging companies rapidly gain ground. The data underscores the importance of innovation and strategic growth in the pharmaceutical sector, offering valuable insights for investors and industry enthusiasts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025